Neuroendocrine Tumors (NETs)

Neuroendocrine tumors (NETs) are a diverse family of neoplasms arising from neuroendocrine cells scattered throughout the body — cells that share properties of both neurons and endocrine glands, secreting hormones, neuropeptides, and biogenic amines. This heterogeneity means NETs range from indolent, incidentally discovered lesions (such as a small appendiceal carcinoid) to aggressive, rapidly fatal cancers (such as small-cell lung cancer or Merkel cell carcinoma). Understanding the spectrum of NET biology, the functional syndromes they produce, and the remarkable expansion of targeted therapies in recent years is essential for optimal patient care.

Table of Contents

1. Overview and Classification
2. Epidemiology
3. Pathophysiology and WHO Grading
4. Primary Sites and Behavior
5. Carcinoid Syndrome
6. Pancreatic NETs
7. Diagnosis and Imaging
8. Treatment
9. Prognosis
10. Key Research Papers
11. PubMed Topic Searches
12. Connections
13. Featured Videos

1. Overview and Classification

The term "neuroendocrine tumor" encompasses a wide spectrum of neoplasms that were historically called "carcinoids" when arising in the gastrointestinal tract and lungs. Today, the World Health Organization (WHO) uses a unified grading system based on proliferative activity to classify all NETs regardless of anatomic origin:

• Well-differentiated NETs (Grade 1–3): Retain the morphologic appearance of normal neuroendocrine cells, with organoid architecture, uniform nuclei, and finely granular cytoplasm. Grade 1 (G1) tumors have Ki-67 proliferative index <3% and fewer than 2 mitoses per 10 high-power fields; G2 tumors have Ki-67 3–20%; G3 well-differentiated NETs (Ki-67 >20%) are a recently recognized high-grade category with behavior worse than G1/2 but better than neuroendocrine carcinoma.
• Poorly differentiated neuroendocrine carcinomas (NEC): High-grade tumors (Ki-67 typically >55%) with loss of neuroendocrine morphology, frequent TP53 and RB1 mutations, and behavior similar to small-cell lung cancer. The two subtypes are small-cell NEC and large-cell NEC. NECs are biologically distinct from well-differentiated G3 NETs and require different treatment algorithms.

The distinction between well-differentiated NET and poorly differentiated NEC is not merely semantic — it has profound implications for prognosis and treatment selection. Well-differentiated NETs, even at Grade 3, typically respond poorly to platinum-based chemotherapy that works well in NEC.

Back to Table of Contents

2. Epidemiology

The incidence of NETs has increased approximately five-fold over the past four decades, from 1.09 per 100,000 in 1973 to 6.98 per 100,000 in 2012, a trend attributed partly to improved detection through widespread use of endoscopy and cross-sectional imaging rather than solely to a true rise in incidence. The estimated prevalence in the United States now exceeds 170,000 — greater than that of pancreatic cancer, gastric cancer, or hepatocellular carcinoma — making NETs a significant oncologic burden.

Key epidemiologic features:

• Median age at diagnosis: Approximately 60 years for GI NETs; earlier for some functional pancreatic NETs such as insulinoma.
• Sex: Slight female predominance for GI NETs overall; males slightly predominate for pancreatic NETs.
• Race: Higher incidence in Black Americans compared to White Americans for small intestinal NETs.
• Hereditary syndromes: Multiple endocrine neoplasia type 1 (MEN1, MEN1 gene mutation) is associated with pancreatic NETs, pituitary adenomas, and primary hyperparathyroidism. Von Hippel-Lindau syndrome (VHL mutation) predisposes to pancreatic NETs and hemangioblastomas. Tuberous sclerosis complex and neurofibromatosis type 1 (NF1) are less commonly associated with duodenal somatostatinomas and GI NETs, respectively.

Back to Table of Contents

3. Pathophysiology and WHO Grading

Neuroendocrine cells throughout the body share a common functional toolkit: the ability to synthesize and store bioactive amines and peptides in dense-core secretory granules, and to release these substances in response to neural, hormonal, or paracrine signals. Key shared markers reflecting this biology include:

• Chromogranin A (CgA): A secretogranin present in virtually all neuroendocrine secretory granules; the most widely used general serum biomarker for NET. Elevated in 60–90% of patients with functioning NETs and in a substantial proportion of non-functioning tumors. CgA levels correlate with tumor burden and can be used for monitoring response to therapy.
• Synaptophysin: A synaptic vesicle membrane protein; highly sensitive (but less specific) immunohistochemical marker for neuroendocrine differentiation.
• Neuron-specific enolase (NSE): Less specific than CgA but useful for poorly differentiated NECs.
• Somatostatin receptors (SSTR): Expressed on the surface of most well-differentiated NETs, particularly SSTR2 and SSTR5. Expression of these receptors is both diagnostically useful (enabling radiolabeled somatostatin receptor imaging) and therapeutically exploitable (somatostatin analogs, PRRT).

Molecularly, well-differentiated NETs harbor mutations in genes regulating the mTOR pathway (PTEN, TSC1/TSC2, PIK3CA), chromatin remodeling (MEN1, DAXX, ATRX), and DNA damage response. Loss of DAXX and ATRX — seen in ~40% of pancreatic NETs — activates an alternative lengthening of telomeres (ALT) mechanism and is associated with worse prognosis.

The WHO 2019 classification applies the G1/G2/G3/NEC framework across all sites (pancreas, GI tract, lung), creating for the first time a truly unified grading system that facilitates cross-study comparisons and treatment algorithm design.

Back to Table of Contents

4. Primary Sites and Behavior

NETs can arise throughout the gastrointestinal tract, pancreas, lungs, thymus, and adrenal glands. Behavior varies markedly by site:

• Small intestine (ileum/jejunum): The most common site for GI NETs in current series. The majority are serotonin-secreting and can cause carcinoid syndrome upon hepatic metastasis. Small intestinal NETs frequently present as multiple primary tumors (up to 30% are multicentric) and often form a characteristic desmoplastic fibrotic reaction in the mesentery ("mesenteric retraction") that can cause intestinal ischemia and obstruction. The primary tumor is frequently small (<2 cm) but lymph node and liver metastases are present in up to 75% of patients at diagnosis.
• Rectum: The most common GI NET in Asian populations. Most rectal NETs are small (<1 cm), non-functioning, discovered incidentally on colonoscopy, and have excellent prognosis. Larger tumors (>2 cm) carry substantial metastatic potential.
• Appendix: The classic location of the "carcinoid tumor" first described. Most are small (<2 cm), discovered incidentally at appendectomy, and almost never metastasize. Tumors >2 cm at the base of the appendix may require right hemicolectomy.
• Stomach: Three subtypes with distinct biology and management. Type 1 (ECL-cell hyperplasia in chronic atrophic gastritis/pernicious anemia, hypergastrinemia-driven, excellent prognosis) and Type 2 (MEN1/Zollinger-Ellison syndrome) are generally indolent. Type 3 (sporadic, normal gastrin) behaves aggressively and requires surgical resection.
• Pancreas: Covered separately below due to the importance of functional syndromes.
• Lung: Typical carcinoid (G1/2, well-differentiated, 10-year survival >85%) vs. atypical carcinoid (G2/3, worse prognosis) vs. large-cell NEC and small-cell lung cancer (high-grade, highly lethal).

Back to Table of Contents

5. Carcinoid Syndrome

Carcinoid syndrome is the classic functional syndrome of midgut (small intestinal) NETs and occurs when tumor secretory products — principally serotonin, but also bradykinin, tachykinins, prostaglandins, and histamine — reach the systemic circulation without hepatic first-pass inactivation. This typically requires either hepatic metastases (most common, as portal venous blood from gut bypasses hepatic inactivation only when liver is diffusely replaced by tumor) or primary retroperitoneal/lung NETs that drain directly into systemic veins.

The classic triad of carcinoid syndrome comprises:

• Flushing (85–95%): Episodic erythema of the face, neck, and upper chest; may be triggered by alcohol, certain foods, exercise, or stress. Prolonged or severe flushing episodes can be associated with telangiectasias over time.
• Diarrhea (70–80%): Secretory diarrhea (persists despite fasting), often watery and high-volume, due to serotonin-stimulated intestinal hypermotility and secretion.
• Wheezing/Bronchospasm (15–20%): Less common; mediated by histamine and bradykinin.

Carcinoid heart disease (Hedinger syndrome) represents a devastating complication occurring in up to 50% of patients with carcinoid syndrome. Circulating serotonin causes endocardial fibrosis (plaque deposition) that preferentially affects the right heart valves — typically tricuspid regurgitation and pulmonary valve stenosis — because the lungs efficiently inactivate serotonin before blood reaches the left heart. Left-sided valvular lesions occur only in the presence of patent foramen ovale or with pulmonary NETs. Echocardiography should be performed at diagnosis and annually in patients with carcinoid syndrome; cardiac biomarkers (BNP, NT-proBNP) are useful screening tools. Valve replacement may be required in advanced disease before other systemic therapies.

Carcinoid crisis is a life-threatening exacerbation of carcinoid syndrome precipitated by anesthesia induction, tumor manipulation (surgery, biopsy, embolization), or stress. It manifests as hemodynamic instability (hypotension or hypertension), bronchospasm, altered consciousness, and profound flushing. Prevention requires preoperative octreotide loading (intravenous octreotide infusion peri-procedurally) and close communication with the anesthesia team. Intraoperative crisis is treated with IV octreotide boluses.

Serotonin levels can be monitored via urinary 5-hydroxyindoleacetic acid (5-HIAA), the principal metabolite of serotonin, measured in a 24-hour urine collection. Elevations >2–3 times the upper limit of normal are highly specific for serotonin-secreting NETs. Patients should avoid serotonin-rich foods (bananas, pineapple, avocado, walnuts) for 48–72 hours before collection to avoid false positives.

Back to Table of Contents

6. Pancreatic NETs (pNETs)

Pancreatic NETs represent approximately 10% of all NETs but disproportionately attract clinical and research attention because of their dramatic functional syndromes, association with hereditary syndromes, and the development of targeted therapies specifically demonstrated in pNETs. They are classified as functional (secreting biologically active hormones causing recognizable syndromes) or non-functional (hormonally silent, typically larger at diagnosis):

• Insulinoma: The most common functional pNET (1–4 per million per year); 90% benign and solitary. The hallmark is Whipple's triad: symptomatic hypoglycemia during fasting, blood glucose <55 mg/dL at the time of symptoms, and symptom relief with glucose administration. Diagnosis is confirmed by supervised 72-hour fast with measurement of insulin, C-peptide, proinsulin, and beta-hydroxybutyrate. Inappropriately elevated insulin and C-peptide with low glucose confirms endogenous hyperinsulinism; exogenous insulin suppresses C-peptide.
• Gastrinoma (Zollinger-Ellison Syndrome, ZES): Excess gastrin secretion causes hypersecretion of gastric acid leading to multiple peptic ulcers (often distal duodenal or jejunal), diarrhea, and esophagitis. Serum fasting gastrin >1,000 pg/mL (with gastric pH <2) is diagnostic; a secretin stimulation test (paradoxical gastrin rise) is used for intermediate values. Approximately 25% of gastrinomas are associated with MEN1. The "gastrinoma triangle" (junction of cystic and common bile ducts superiorly, junction of second and third portions of duodenum inferiorly, and neck/body of pancreas medially) harbors most tumors.
• Glucagonoma: Rare; causes the distinctive necrolytic migratory erythema (NME) — a blistering, crusting rash at perioral/perineal/intertriginous sites — along with diabetes mellitus, weight loss, hypoalbuminemia, and anemia. The rash results from hypoaminoacidemia (glucagon catabolizes amino acids) and zinc deficiency; parenteral nutrition often causes rapid dermatologic improvement.
• VIPoma (Verner-Morrison syndrome, WDHA syndrome): Vasoactive intestinal peptide (VIP) secretion causes profuse watery diarrhea (>3 L/day), hypokalemia, and achlorhydria. Electrolyte replacement is urgent; octreotide reduces secretory diarrhea while surgery/ablation is planned.
• Somatostatinoma: Extremely rare; inhibitory effects of somatostatin produce the "inhibitory syndrome": diabetes mellitus (insulin suppression), cholelithiasis (decreased gallbladder contraction), and steatorrhea (inhibition of pancreatic exocrine secretion). Most are non-functional or diagnosed at advanced stage.
• Non-functional pNETs: Account for the majority of pNETs at diagnosis. They are typically diagnosed incidentally or when large enough to cause mass effect (obstructive jaundice, abdominal pain). The recent trend toward increased detection of small non-functional pNETs on imaging has prompted active surveillance protocols for asymptomatic tumors <2 cm in the absence of worrisome features.

Back to Table of Contents

7. Diagnosis and Imaging

A comprehensive diagnostic evaluation integrates biochemical markers, anatomic imaging, and functional somatostatin receptor imaging:

• Biochemical markers: Chromogranin A (CgA) is the universal NET marker; 24-hour urinary 5-HIAA for serotonin-secreting tumors; specific hormones (insulin/C-peptide, gastrin, glucagon, VIP, somatostatin) guided by clinical syndrome. Pancreastatin (a CgA fragment) may outperform CgA for monitoring in some centers. Note that proton pump inhibitors, renal insufficiency, hypertension, and inflammatory conditions can spuriously elevate CgA.
• CT/MRI abdomen: Baseline anatomic imaging; small intestinal NETs are hypervascular (enhance on arterial phase). MRI with liver-specific contrast (gadoxetate) is superior for detecting liver metastases. Endoscopic ultrasound (EUS) is the most sensitive modality for localizing small pancreatic NETs (<1 cm).
• Ga-68 DOTATATE PET/CT (Netspot): FDA-approved in 2016; the gold standard functional imaging modality for well-differentiated, SSTR-expressing NETs. Sensitivity 90–96%, far superior to conventional octreotide scintigraphy (OctreoScan). DOTATATE PET detects lesions undetectable by CT/MRI and changes management in approximately 30–40% of patients. A positive scan also confirms SSTR expression, making the patient a candidate for PRRT.
• FDG-PET/CT: Indicated for poorly differentiated, high-grade NECs (which downregulate SSTR2 while upregulating glucose metabolism). For well-differentiated NETs, FDG-PET is generally insensitive.
• Tissue diagnosis: Biopsy for histologic confirmation and Ki-67 grading is mandatory before initiating systemic therapy. Ki-67 is typically determined by immunohistochemistry and expressed as the percentage of tumor cells with positive nuclear staining.

Back to Table of Contents

8. Treatment

Treatment of NETs is multimodal and highly individualized based on tumor grade, primary site, extent of disease, SSTR expression, and functional status:

• Surgery: The only curative modality. Even for metastatic disease, cytoreductive surgery (>90% tumor debulking) may provide durable symptom control in selected patients with carcinoid syndrome. Appendiceal NETs <2 cm: appendectomy sufficient. Small intestinal NETs: resection of primary + involved mesentery + lymph nodes (even with distant metastases, to prevent mesenteric ischemia). Insulinoma: enucleation or distal pancreatectomy.
• Somatostatin analogs (SSAs): Octreotide LAR (long-acting repeatable) and lanreotide depot are the cornerstone of both anti-secretory (symptom control in carcinoid syndrome) and anti-proliferative therapy. The PROMID trial (octreotide LAR in midgut NETs) and CLARINET trial (lanreotide in non-functioning GI/pNETs) demonstrated progression-free survival benefit. SSAs are considered first-line for G1/G2 SSTR-positive NETs in most guidelines.
• Peptide receptor radionuclide therapy (PRRT): Lutetium-177-DOTATATE (Lutathera) delivers targeted radiation to SSTR-expressing tumor cells. The NETTER-1 trial (2017) demonstrated significantly improved PFS (not reached vs. 8.4 months) and a 79% reduction in the risk of disease progression or death compared to high-dose octreotide in midgut NETs. FDA-approved 2018 for SSTR-positive G1/G2 GEP-NETs. Requires adequate renal function; renal-protective amino acid infusion co-administered.
• mTOR inhibition: Everolimus (Afinitor) is FDA-approved for progressive, well-differentiated G1/G2 pNETs (RADIANT-3 trial), non-functional GI/lung NETs (RADIANT-4 trial), and carcinoid syndrome-associated functional tumors (RADIANT-2). Mechanism: mTOR pathway hyperactivation is common in NETs due to PTEN/TSC mutations.
• Sunitinib: Anti-angiogenic/tyrosine kinase inhibitor FDA-approved for progressive pNETs. The SUN11654 trial demonstrated improved PFS (11.4 vs. 5.5 months) vs. placebo.
• Hepatic-directed therapies: For liver-dominant metastatic disease: transarterial embolization (TAE), transarterial chemoembolization (TACE), and selective internal radiation therapy (SIRT/radioembolization with Y-90) can provide disease control and symptom palliation.
• Chemotherapy: Streptozocin-based regimens (streptozocin + 5-fluorouracil, or streptozocin + doxorubicin) for advanced pNETs. Platinum-based chemotherapy (cisplatin/etoposide) for poorly differentiated NECs. Temozolomide-based regimens are used for pancreatic NETs with MGMT promoter methylation.
• Telotristat ethyl (Xermelo): Oral tryptophan hydroxylase inhibitor approved for carcinoid syndrome diarrhea inadequately controlled by SSAs. Reduces intestinal serotonin synthesis directly at the source.

Back to Table of Contents

9. Prognosis

Prognosis varies enormously across the NET spectrum. Well-differentiated G1 small intestinal NETs without distant metastases have 10-year survival rates exceeding 90%. Once liver metastases are present, 5-year survival for G1/G2 GI-NETs is approximately 56–80%. Pancreatic NETs have a worse prognosis than GI-NETs stage for stage, with 5-year overall survival of 50–70% for localized disease and approximately 25–30% for metastatic pNETs, though survival has improved substantially with the approval of everolimus, sunitinib, and PRRT. Poorly differentiated NECs carry a median survival of less than one year even with platinum-based chemotherapy, analogous to small-cell lung cancer.

Prognostic factors include WHO grade (Ki-67), primary site, presence and extent of liver metastases, performance status, loss of DAXX/ATRX expression (pNETs), and SSTR2 expression level (predicts PRRT response). The NET field is moving rapidly toward molecular profiling-guided treatment selection, with several liquid biopsy platforms (NETest) and genomic assays under investigation.

Back to Table of Contents

Key Research Papers

1. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934–959. PMID: 12569593 | DOI: 10.1002/cncr.11105
2. Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656–4663. PMID: 19704057 | DOI: 10.1200/JCO.2009.22.8510
3. Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224–233. PMID: 25014687 | DOI: 10.1056/NEJMoa1316158
4. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514–523. PMID: 21306238 | DOI: 10.1056/NEJMoa1009290
5. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501–513. PMID: 21306237 | DOI: 10.1056/NEJMoa1003825
6. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–135. PMID: 28076709 | DOI: 10.1056/NEJMoa1607427
7. Kulke MH, Hörsch D, Caplin ME, et al. Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. J Clin Oncol. 2017;35(1):14–23. PMID: 28094194 | DOI: 10.1200/JCO.2016.69.2780
8. Jann H, Roll S, Couvelard A, et al. Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer. 2011;117(15):3332–3341. PMID: 21319148 | DOI: 10.1002/cncr.25855
9. Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–1342. PMID: 28448665 | DOI: 10.1001/jamaoncol.2017.0589
10. Scarpa A, Chang DK, Nones K, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017;543(7643):65–71. PMID: 28199314 | DOI: 10.1038/nature21063
11. Niederle MB, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification. Endocr Relat Cancer. 2010;17(4):909–918. PMID: 20702723 | DOI: 10.1677/ERC-10-0152
12. Grozinsky-Glasberg S, Grossman AB, Gross DJ. Carcinoid heart disease: from pathophysiology to treatment — 'something in the way it moves'. Neuroendocrinology. 2015;101(4):263–273. PMID: 25871533 | DOI: 10.1159/000381930

Back to Table of Contents

PubMed Topic Searches

1. Neuroendocrine tumor treatment
2. Carcinoid syndrome management
3. Lutetium-177 DOTATATE PRRT
4. Pancreatic NET diagnosis
5. Insulinoma hypoglycemia surgery
6. Zollinger-Ellison syndrome gastrinoma
7. Chromogranin A NET biomarker
8. Ga-68 DOTATATE PET imaging
9. Somatostatin analog octreotide
10. MEN1 pancreatic neuroendocrine
11. Carcinoid heart disease
12. Neuroendocrine carcinoma chemotherapy

Back to Table of Contents

Connections

• Cancer Overview
• Pancreatic Cancer
• Thyroid Cancer
• Irritable Bowel Syndrome
• Crohn's Disease
• Diabetes
• Metastatic Cancers
• Lung Cancer
• Carcinoid Syndrome
• Hypoglycemia
• Chromogranin A Lab Test
• Diarrhea

Back to Table of Contents

Featured Videos